It is a testament to how smooth and predictable the US regulatory climate has been for the past few years that a recent spate of negative regulatory updates prompted such a strong reaction among biotech investors.
Is The US FDA At A Tipping Point?
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.
